Lack of increased cardiac toxicity with sequential doxorubicin and paclitaxel

Cancer Investigation

Volumn 16, Issue 2, 1998, Pages 67-71

  Hudis, Clifford ^a   Riccio, Louise ^a   Seidman, Andrew ^a   Baselga, Jose ^a   Currie, Violante ^a   Fennelly, David ^a   Gilewski, Teresa ^a   Lebwohl, David ^a   Moynahan, Maryellen ^a   Raptis, George ^a   Surbone, Antonella ^a   Sklarin, Nancy ^a   Yao, T J ^a   Keefe, Deborah ^b   Norton, Larry ^a  

^a WEILL CORNELL MEDICAL COLLEGE   (United States)

^b MEMORIAL SLOAN KETTERING CANCER CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

DOXORUBICIN; PACLITAXEL;

ADULT; ANTINEOPLASTIC ACTIVITY; ARTICLE; BREAST CANCER; BREAST METASTASIS; CANCER COMBINATION CHEMOTHERAPY; CARDIOTOXICITY; CLINICAL ARTICLE; HUMAN; INTRAVENOUS DRUG ADMINISTRATION; PRIORITY JOURNAL; SOLID TUMOR; TREATMENT OUTCOME;

EID: 14444276265     PISSN: 07357907     EISSN: None     Source Type: Journal    
DOI: 10.3109/07357909809039759     Document Type: Article

References (11)

1. Bonadonna G, Monfardini S, DeLena M: Phase I and preliminary phase II evaluation of Adriamycin (NSC-123127). Cancer Res 30:2572-2582, 1970.
2. Reichman BS, Seidman AD, Crown JP, et al: Paclitaxel and recombinant human granulocyte colony-stimulating factor as initial chemotherapy for metastatic breast cancer. J Clin Oncol 10:1943-1951, 1993.
3. Fisherman JS, McCabe M, Noone M, et al: Phase I study of Taxol, doxorubicin, plus granulocyte colony-stimulating factor in patients with metastatic breast cancer. Monogr Natl Cancer Inst 15:189-194, 1993.
4. Buzdar AM, Holmes FA, Hortobagyi GN: Paclitaxel in the treatment of metastatic breast cancer: M.D. Anderson Cancer Center experience. Semin Oncol 22(3 Suppl 6): 101-104, 1995.
5. Sledge GW, Goldstein RN, Sparano J, et al: Phase I trial of Adriamycin and Taxol in metastatic breast cancer. Proc Eur Conf Clin Oncol 7:A421, 1993 (abstract).
6. Gianni L, Munzone E, Capri G., et al: Paclitaxel by 3-hour infusion in combination with bolus doxorubicin in women with untreated metastatic breast cancer: High antitumor efficacy and cardiac effects in a dose-finding and sequence-finding study. J Clin Oncol 13:2688-2699, 1995.
7. Dombernowsky P, Gehl J, Ejlersen B, Boesgaard M: Treatment of metastatic cancer with paclitaxel and doxorubicin. In: Emerging Strategies in Medical Oncology. European Society for Medical Oncology. Lisbon, Portugal, 19th Congress, Nov 18-22, 1994, pp 5-6.
8. Hudis C, Seidman A, Baselga J, et al: Sequential adjuvant therapy with doxorubicin/paclitaxel/cyclophosphamide for resectable breast cancer involving four or more axillary nodes. Semin Oncol 22 (4 Suppl L):1-6, 1995.
9. Allen A: The cardiotoxicity of chemotherapeutic drugs. Semin Oncol 5:529-542, 1992.
10. VonHoff DD, Layard MW, Basa P, et al: Risk factors for doxorubicin-induced congestive heart failure. Ann Intern Med 91:710-717, 1979.
11. Rowinsky E, Donehower R: Paclitaxel (Taxol). N Engl J Med 15:1004-1014, 1995.